Vectorious Medical Technologies is a technology company.
Vectorious Medical Technologies has raised $15.0M across 2 funding rounds.
Vectorious Medical Technologies has raised $15.0M in total across 2 funding rounds.
Vectorious Medical Technologies is a medical technology company specializing in cardiovascular health, particularly heart failure management. Their flagship product, the V-LAP System, is an implantable microcomputer sensor placed in the heart’s interatrial septum that continuously measures left atrial pressure (LAP). This data enables early detection of heart failure exacerbations and supports physician-guided, patient self-management through a connected app. By providing real-time, remote monitoring of cardiac pressure, Vectorious aims to reduce hospitalizations and improve quality of life for heart failure patients[1][2].
Founded in 2011 and based in Tel Aviv, Israel, Vectorious serves healthcare providers and patients managing chronic heart failure. Their technology addresses the critical problem of late detection of heart failure deterioration by enabling proactive treatment adjustments before symptoms worsen. The company has demonstrated growth momentum through clinical validation and expanding data collection, currently holding the largest LAP dataset worldwide[1][2].
Vectorious Medical Technologies was founded in 2011 in Tel Aviv by a team including Eyal Orion, MD, who serves as CEO. The idea emerged from the need for better monitoring tools in heart failure, a condition with high morbidity and hospitalization rates. The founders leveraged advances in microelectronics and implantable sensors to develop an in-heart microcomputer capable of measuring LAP directly, a key indicator of heart failure status. Early clinical trials showed significant reductions in heart failure-related hospitalizations and improvements in patient quality of life, providing pivotal validation for the technology[1].
Vectorious is riding the growing trend of digital health and remote patient monitoring, particularly in chronic disease management. The timing is favorable due to increasing healthcare costs, aging populations, and the shift toward value-based care models emphasizing prevention and outpatient management. Their implantable sensor technology integrates with telemedicine and AI-driven analytics, positioning them at the intersection of medical devices and digital therapeutics. By enabling earlier intervention in heart failure, Vectorious influences the broader ecosystem by potentially reducing hospital burden and improving patient outcomes, aligning with global healthcare priorities[1][2].
Looking ahead, Vectorious is poised to expand clinical activities, particularly in the U.S., working closely with regulatory bodies like the FDA and healthcare providers to conduct pivotal trials. Trends such as AI integration, personalized medicine, and remote monitoring will shape their journey, potentially broadening their platform’s applications beyond heart failure. Their influence may grow as healthcare systems increasingly adopt implantable and connected devices for chronic disease management, making Vectorious a key player in transforming cardiovascular care.
In summary, Vectorious Medical Technologies combines innovative implantable sensor technology with digital health to address a critical gap in heart failure management, offering promising clinical and economic benefits in a rapidly evolving healthcare landscape[1][2].
Vectorious Medical Technologies has raised $15.0M in total across 2 funding rounds.
Vectorious Medical Technologies's investors include Bain Capital Ventures, Cedar Capital Group, Dell Technologies Capital, Koch Fund, SoftBank Investment Advisers, Tamar Technology Ventures, TCV, Uncorrelated Ventures, Viola Ventures.
Vectorious Medical Technologies has raised $15.0M across 2 funding rounds. Most recently, it raised $10.0M Series B in May 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2018 | $10.0M Series B | Bain Capital Ventures, Cedar Capital Group, Dell Technologies Capital, Koch Fund, SoftBank Investment Advisers, Tamar Technology Ventures, TCV, Uncorrelated Ventures, Viola Ventures | |
| Feb 1, 2015 | $5.0M Series A | Bain Capital Ventures, Cedar Capital Group, Dell Technologies Capital, Koch Fund, SoftBank Investment Advisers, Tamar Technology Ventures, TCV, Uncorrelated Ventures, Viola Ventures |